Analgesic drug using PAC1 receptor antagonistic drug
11365194 · 2022-06-21
Assignee
Inventors
- Takashi Kurihara (Kagoshima, JP)
- Ichiro Takasaki (Toyama, JP)
- Naoki Toyooka (Toyama, JP)
- Hiroaki Gouda (Tokyo, JP)
Cpc classification
C07D403/12
CHEMISTRY; METALLURGY
International classification
Abstract
This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), ##STR00001##
wherein R.sup.1 is a C.sub.1-6-alkoxy group or a C.sub.1-6-haloalkoxy group; R.sup.2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
Claims
1. A compound represented by the following formula (I), ##STR00015## wherein R.sup.1 is a C.sub.1-6-haloalkoxy group; and R.sup.2 is a hydrogen atom; or a salt thereof, or a solvate thereof.
2. The compound according to claim 1 or a salt thereof, or a solvate thereof, wherein R.sup.1 is a trifluoromethoxy group in the formula (I).
3. An analgesic drug comprising a compound according to claim 1, a salt thereof, or a solvate thereof.
Description
BRIEF DESCRIPTION OF DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
DESCRIPTION OF EMBODIMENTS
(13) The present invention will be described in detail hereinafter.
(14) Examples of the C.sub.1-6-alkoxy group represented by R.sup.1 in the formula (I) include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, a pentyloxy group, an isopentyloxy group, a hexyloxy group, a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group and a cyclohexyloxy group.
(15) Examples of the C.sub.1-6-haloalkoxy group represented by R in the formula (I) include a trifluoromethoxy group.
(16) An indazolyl group substituted with a halogen atom and represented by R in the formula (II) is not particularly limited as long as it is an indazolyl group substituted with at least one halogen atom selected from fluorine atoms, chlorine atoms, bromine atoms and iodine atoms (preferably chlorine atom). However, preferable examples thereof include a 3-indazolyl group substituted with at least one chlorine atom.
(17) Examples of the aralkyl group represented by R in the formula (II) include a benzyl group and a phenethyl group.
(18) The phenyl and aralkyl group represented by R in the formula (II) may be substituted with one or more substituents selected from a C.sub.1-6-alkyl group (for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group (1-methylpropyl group), a tert-butyl group, a pentyl group, an isopentyl group, 1-ethylpropyl group, a hexyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group and a cyclohexyl group), a C.sub.1-6-alkoxy group (for example, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, a pentyloxy group, an isopentyloxy group, a hexyloxy group, a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group and a cyclohexyloxy group), a methylenedioxy group, a C.sub.2-6-alkenyloxy group, an aralkyloxy group (for example, a benzyloxy group, a 4-methylbenzyloxy group, a 3-methylbenzyloxy group, a 2-methylbenzyloxy group, a 4-fluorobenzyloxy group, a 3-fluorobenzyloxy group, a 4-chlorobenzyloxy group and a 3-chlorobenzyloxy group), a halogen atom (such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom), a C.sub.1-6-haroalkyl group, a C.sub.1-6-haroalkoxy group, a substituted or unsubstituted phenyl group, an acyl group (for example, a C.sub.1-6-aliphatic acyl group such as a formyl group, an acetyl group, a propanoyl group, a butanoyl group, a pentanoyl group and a hexanoyl group; and an aroyl group such as a benzoyl group and a toluoyl group), an acyloxy group (for example, a C.sub.1-6-aliphatic acyloxy group such as a formyloxy group, an acetoxy group, a propanoyloxy group, a butanoyloxy group, a pentanoyloxy group and a hexanoyloxy group; and an aroyloxy group such as a benzoyloxy group and a toluoyloxy group), a hydroxyl group, a carboxyl group, an acetamido group, a carbamoyl group, a cyano group, a nitro group, and the like.
(19) Among the compounds represented by the formula (I), compounds wherein R.sup.1 is a C.sub.1-6-haroalkoxy group, for example, a trifluoromethoxy group are preferable.
(20) Among the compounds represented by the formula (II), compounds wherein R is a 3-indazolyl group substituted with at least one chlorine atom are preferable.
(21) Among the compounds represented by the formula (II), the compounds represented by the following formula (IIa).
(22) ##STR00008##
wherein R′ is an indazolyl group substituted with a halogen atom; a phenyl group which may be substituted with a methyl group, a fluorine atom, a methoxy group, a cyano group or a hydroxyl group; a pyrazolyl group; or a substituted aralkyl group:
are novel compounds.
(23) The salt of a compound represented by the formula (I) or (II) is preferably a pharmaceutically acceptable salt, and examples of the salt include a salt of the compound with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, nitric acid, pyrosulfuric acid and metaphosphoric acid or with an organic acid such as citric acid, benzoic acid, acetic acid, propionic acid, fumaric acid, maleic acid and sulfonic acid (for example, methanesulfonic acid, p-toluene sulfonic acid, naphthalene sulfonic acid).
(24) Examples of a solvate of a compound represented by the formula (I) or (II), or a salt thereof include a hydrate.
(25) A compound represented by the formula (I) can be produced, for example, according to the method described in Shi, D. Q. et al. J. Heterocyclic Chem. 2009, 46, 1331-1334, or Tu. S. et al. Bioorg. Med. Chem. Lett. 2006, 16, 3578-3581, as follows.
(26) ##STR00009##
wherein R.sup.1 and R.sup.2 have the same meaning as defined in the formula (I).
(27) Specifically, a target compound (I) can be manufactured by heating and reacting the corresponding aromatic aldehyde compound, 2,4-diamino-6-hydroxypyrimidine (another name: 2,6-diaminopyrimidin-4(3H)-one) and Meldrum's acid, (i) in water in the presence of triethylbenzylammonium chloride, (ii) while being irradiated with a microwave, or (iii) in an organic solvent.
(28) A compound represented by the formula (II) can be produced, for example, according to the method described in JP Patent Publication (Kohyo) 2006-510596 A, as follows.
(29) ##STR00010##
wherein R has the same meaning as defined in the formula (II).
(30) Specifically, a target compound (II) can be manufactured by reacting the corresponding amine compound and itaconic acid to convert them into γ-lactam carboxylic acid, and then reacting the γ-lactam carboxylic acid with histamine in the presence of a condensing agent (for example, carbodiimide).
(31) The product obtained as mentioned above may be purified by a customary method, for example, column chromatography using, e.g., silica gel, as a carrier and a recrystallization method using, e.g., methanol, ethanol, chloroform, dimethyl sulfoxide, n-hexane-ethyl acetate or water. Examples of an elution solvent for column chromatography include methanol, ethanol, chloroform, acetone, hexane, dichloromethane, ethyl acetate and mixed solvents of these.
(32) The compound as mentioned above can be used as an analgesic drug in combination with a customary pharmaceutical carrier. The dosage form thereof is not particularly limited and appropriately selected and used depending on needs. Examples of the dosage form include oral agents such as a tablet, a capsule, a granule, a fine granule, a powder, a sustained release preparation, a liquid preparation, a suspension, an emulsion, a syrup and an elixir and parenteral agents such as an injection and a suppository.
(33) An oral agent is produced by using, for example, starch, lactose, sucrose, mannitol, carboxymethylcellulose and inorganic salts in accordance with an ordinary method. In addition to these components, e.g., a binder, a disintegrant, a surfactant, a lubricant, a glidant, a flavoring agent, a colorant and/or a perfume can be appropriately added.
(34) Examples of the binder include starch, dextrin, gum Arabic, gelatin, hydroxypropyl starch, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, ethylcellulose, polyvinyl pyrrolidone and macrogol.
(35) Examples of the disintegrant include starch, hydroxypropyl starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose and a low-substituted hydroxypropylcellulose.
(36) Examples of the surfactant include sodium lauryl sulfate, soy lecithin, sucrose fatty acid ester and polysorbate 80.
(37) Examples of the lubricant include talc, wax, hydrogenated vegetable oil, sucrose fatty acid ester, magnesium stearate, calcium stearate, aluminum stearate and polyethylene glycol.
(38) Examples of the glidant include light anhydrous silicic acid, dry aluminum hydroxide gel, synthetic aluminum silicate and magnesium silicate.
(39) An injection is produced in accordance with an ordinary method. As a diluent, generally, distilled water for injection, saline, a glucose solution, olive oil, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol, polyethylene glycol, and/or the like can be used. If necessary, a disinfectant, a preservative, a stabilizer, an isotonic agent, a soothing agent, and/or the like may be added. In view of stability, an injection can be added in, e.g., a vial, frozen and subjected to ordinary lyophilization to remove a water content. From the lyophilized injection, a liquid preparation can be prepared again immediately before use. The content of a compound of the formula (I) or (II) in the injection may be varied between the 5 and 50 wt %; however, the content is not limited to this.
(40) Examples of other parenteral agents include a suppository for intrarectal administration. The suppository can be produced in accordance with an ordinary method.
(41) The administration schedule of an analgesic drug formulated varies depending on, e.g., the dosage form and the route of administration, and, for example, can be administered once to four times per day in a period from a week to 3 months.
(42) In order to obtain a desired effect, the dose of an oral agent, which varies depending on the age, body weight and severity of a disease of a patient, is usually, for example, 0.1 to 1000 mg and preferably 1 to 500 mg per adult in terms of the weight of a compound of the formula (I) or (II), and suitably divided into several portions per day and administered.
(43) In order to obtain a desired effect, the dose of a parenteral agent, which varies depending on the age, body weight and severity of a disease of a patient, is usually, for example, 0.1 to 1000 mg and preferably 1 to 500 mg per adult in terms of the weight of a compound of the formula (I) or (II), and suitably administered by intravenous injection, intravenous drip infusion, subcutaneous injection or intramuscular injection.
(44) The analgesic drug according to the present invention can be used for treating and/or preventing a disease or symptom selected from the group consisting of neuropathic pain (for example, peripheral neuropathic pain associated with external wound, and peripheral neuropathic pain associated with cancer chemotherapy), pain associated with cancer chemotherapy, diabetic neuralgia, diabetic peripheral neuropathic pain, and migraine.
(45) This description includes part or all of the content as disclosed in the description and/or drawing of Japanese Patent Application No. 2017-186447, which is a priority document of the present application.
EXAMPLES
(46) Now, the present invention will be more specifically described below by way of Examples; however, the scope of the present invention is not limited to them.
[Example 1] Synthesis of Pyrido[2,3-d]Pyrimidine Derivatives
(47) ##STR00011## ##STR00012##
(48) aldehydes (1a, b, d, e, f, g, j, k, m, n, o, p, q and r) and the aldehydes known in Literatures (1c, h, i, l, s and t) in ethylene glycol (0.5 mL) were sequentially added at room temperature 2,4-diamino-6-hydroxypyrimidine (0.67 mmol) and Meldrum's acid (1.00 mmol), and the mixture was stirred at 100° C. for 20 hours in an Ar atmosphere in accordance with a method described in Literature.sup.1. The reaction liquid was let to cool, then filtered, and further washed with methanol (0.5 mL×3) to obtain pale yellow crystals 2a to u, respectively.
2-Amino-5-(4-ethoxy-3-methylphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2a)
(49) Yield: 46%; mp: >300° C.; IR (KBr): 3455, 3166, 2856, 2699, 1578, 1477 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.55 (1H, br s), 10.01 (1H, s), 6.90 (1H, d, J=2.4 Hz), 6.84 (1H, dd, J=8.8, 2.4 Hz), 6.77 (1H, d, J=8.8 Hz), 6.51 (2H, br s), 4.00 (1H, d, J=7.6 Hz), 3.95 (2H, q, J=7.0 Hz), 2.88 (1H, dd, J=16.0, 7.6 Hz), 2.42 (1H, d, J=16.0 Hz), 2.07 (3H, s), 1.29 (3H, t, J=7.0 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.10, 161.42, 156.45, 155.20, 154.95, 135.08, 128.74, 125.49, 124.61, 111.22, 92.07, 63.14, 32.12, 16.21, 14.83; MS (EI) m/z 314 (M+).
2-Amino-5-(4-ethoxy-3-methoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2b)
(50) Yield: 37%; mp: >300° C.; IR (KBr): 3462, 3309, 2850, 2743, 1582, 1521 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.57 (H, br s), 10.02 (1H, s), 6.84 (1H, d, J=2.3 Hz), 6.78 (1H, d, J=8.7 Hz), 6.53 (1H, dd, J=8.7, 2.3 Hz), 6.50 (2H, br s), 4.05 (1H, d, J=7.7 Hz), 3.92 (2H, q, J=6.9 Hz), 3.69 (3H, s), 2.88 (OH, dd, J=16.4, 7.7 Hz), 1.27 (3H, t, J=6.9 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.34, 161.47, 156.43, 155.01, 148.89, 146.63, 136.09, 117.65, 112.90, 111.24, 92.03, 63.73, 55.38, 38.71, 32.44, 14.81; MS (EI) m/z 330 (M+).
2-Amino-5-(3-methoxy-4-propoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2c)
(51) Yield: 38%; mp: >300° C.; IR (KBr): 3450, 3167, 2959, 2876, 1652, 1591 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.57 (1H, br s), 10.03 (1H, br s), 6.83 (1H, d, J=2.3 Hz), 6.79 (1H, d, J=8.4 Hz), 6.52 (1H, dd, J=8.4.2.3 Hz), 6.51 (2H, br s), 4.05 (1H, d, J=7.9 Hz), 3.82 (2H, t, J=7.1 Hz), 3.69 (3H, s), 2.88 (1H, dd, J=16.4, 7.9 Hz), 1.67 (2H, sext, J=7.1 Hz), 0.92 (3H, t, J=7.1 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.22, 161.69, 158.44, 157.50, 146.831, 145.48, 137.33, 117.79, 113.05, 111.44, 99.65, 69.86, 55.57, 38.73, 32.52, 22.20, 10.53; MS (EI) m/z 344 (M+).
2-Amino-5-(3,4-diethoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2d)
(52) Yield: 41%; mp: >300° C.; IR (KBr): 3188, 2977, 2868, 1653, 1635 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.57 (1H, s), 10.01 (1H, s), 6.81 (1H, d, J=1.8 Hz), 6.78 (1H, d, J=8.8 Hz), 6.53 (1H, dd, J=8.8, 1.8 Hz), 6.50 (2H, br s), 4.03 (1H, d, J=7.8 Hz), 3.93 (2H, q, J=6.9 Hz), 3.92 (2H, q, J=6.9 Hz), 2.87 (1H, dd, J=16.0, 7.8 Hz), 1.28 (3H, t, J=6.9 Hz), 1.26 (3H, t, J=6.9 Hz): .sup.13C NMR (100 MHz, DMSO-d6): δ 171.27, 161.47, 156.42, 154.97, 148.11, 146.87, 136.19, 117.94, 113.45, 112.69, 92.07, 63.83, 63.78, 38.66, 32.37, 14.82; MS (EI) m/z 344 (M+).
2-Amino-5-(3,4-difluorophenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2e)
(53) Yield: 34%; mp: >300° C.; IR (KBr): 3471, 3161, 1646, 1592 cm.sup.−1; .sup.1H-NMR (400 MHz, DMSO-d6): δ 10.62 (1H, br s), 10.13 (1H, br s), 7.32 (1H, dt, J=10.8, 8.4 Hz), 7.18 (1H, ddd, J=10.8, 8.4, 2.4 Hz), 6.95 (1H, m), 6.57 (2H, brs), 4.12 (1H, d, J=7.2 Hz), 2.94 (1H, dd, J=16.3, 7.2 Hz).sup.13C NMR (125 MHz, DMSO-d6): δ 170.86, 161.41, 156.68, 155.24, 149.02, 147.17, 141.45, 122.88, 117.41 (d, J=17.0 Hz), 115.62 (d, J=17.0 Hz), 91.05, 38.22, 32.24; MS (EI) m/z 292 (M+).
2-Amino-5-(3-bromo-4-ethoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2f)
(54) Yield: 40%; mp: >300° C.; IR (KBr): 3458, 3080, 2863, 2751, 1540, 1475 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.57 (1H Kbr s), 10.09 (1H, s), 7.30 (H, d, J=2.4 Hz), 7.06 (1H, dd, J=8.0, 2.4 Hz), 6.99 (1H, d, J=8.0 Hz), 6.56 (2H, br s), 4.09 (1H, m), 4.04 (2H, q. J=7.1 Hz), 2.90 (1H, dd, J=16.2, 6.7 Hz), 1.31 (3H, t, J=7.1 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 170.93, 161.39, 156.55, 155.10, 153.29, 137.33, 130.87, 126.80, 113.77, 110.89, 91.53, 64.39, 38.47, 31.82, 14.58; MS (EI) m/z 379 (M+).
2-Amino-5-(3-ethoxy-4-methoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2g)
(55) Yield: 45%; mp: >300° C.; IR (KBr): 3461, 3160, 2841, 1591, 1516 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.58 (1H, br s), 10.03 (1H, s), 6.82 (1H, d, J=2.4 Hz), 6.80 (1H, d, J=8.4 Hz), 6.55 (1H, dd, J=8.4, 2.4 Hz), 6.50 (1H, brs), 4.04 (1H, d, J=7.8 Hz). 3.96-3.88 (2H, m), 3.68 (3H, s), 2.87 (1H, dd, J=16.0, 7.8 Hz), 1.28 (3H, t, J=7.2 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.30, 161.55, 156.51, 155.00, 147.88, 147.66, 136.10, 117.81, 112.20, 111.90, 92.11, 63.68, 55.54, 38.72, 32.42, 14.83; MS (EI) m/z 330 (M+).
5-(3-Allyloxy-4-methoxyphenyl)-2-amino-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2h)
(56) Yield: 35%; mp: >300° C.; IR (KBr): 3462, 3169, 1636, 1617, 1591 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.58 (1H, br s), 10.02 (1H, s), 6.84 (1H, d, J=2.0 Hz), 6.81 (1H, d, J=8.4 Hz), 6.57 (1H, dd, J=8.4, 2.0 Hz), 5.99 (1H, ddd, J=17.6, 10.4.5.2 Hz), 5.36 (1H, dd, J=17.6, 2.0 Hz), 5.22 (1H, dd, J=10.4.2.0 Hz), 4.46 (2H, d, J=5.2 Hz), 4.03 (1H, d, J=7.2 Hz), 3.68 (3H, s), 2.87 (11H, dd, J=15.8, 7.2 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.16, 158.72, 156.11, 154.99, 147.79, 147.55, 136.10, 133.95, 118.27, 117.88, 112.81, 112.09, 92.02, 69.10, 55.65, 32.41; MS (EI) m/z 342 (M+).
2-Amino-5-(4-methoxy-3-propoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2i)
(57) Yield: 41%; mp: >300° C.; IR (KBr): 3463, 3160, 2846, 1695, 1591, 1539, 1516 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.58 (H, br s), 10.03 (1H, s), 6.82 (1H, d, J=2.4 Hz), 6.80 (1H, dd, J=8.4, 2.4 Hz), 6.55 (1H, d, J=8.4 Hz), 6.51 (2H, br s), 4.04 (1H, d, J=7.2 Hz), 3.84-3.81 (2H, m), 3.67 (3H, s), 2.87 (1H, dd, J=16.4, 7.2 Hz), 1.68 (2H, sext, J=6.8 Hz), 0.94 (3H, t, J=6.8 Hz); .sup.13C NMR (100 MHz, DMSO-d6): 171.24, 161.48, 156.43, 154.96, 148.04, 147.68, 136.14, 117.78, 112.27, 112.04, 92.06, 69.63, 55.61, 38.66, 32.38, 22.12, 10.46; MS (EI) m/z 344 (M+).
2-Amino-5-(3-ethoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2j)
(58) Yield: 43%; mp: >300° C.; IR (KBr): 3447, 3170, 2854, 1592, 1539 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.58 (1H, br s), 10.06 (1H, s), 7.15 (1H, t, J=7.8 Hz), 6.72 (I H, dd, J=7.8, 2.4 Hz), 6.70 (1H, dd, J=7.8, 2.4 Hz), 6.66 (1H, d, J=2.4 Hz), 6.53 (2H, brs), 4.07 (1H, d, J=7.4 Hz), 3.94 (2H, q, J=6.0 Hz), 2.91 (1H, dd, J=16.3, 7.4 Hz), 1.28 (3H, t, J=6.0 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.04, 161.40, 158.57, 156.59, 155.03, 145.32, 129.28, 118.56, 113.19, 111.58, 91.65, 62.78, 38.50, 32.86, 14.65; MS (EI) m/z 300 (M+).
5-(3-Allyloxyphenyl)-2-amino-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2k)
(59) Yield: 45%; mp: >300° C.; IR (KBr): 3085, 2855, 2727, 1520 cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.58 (1H, br s), 10.06 (1H, s), 7.15 (1H, t, J=7.6 Hz), 6.76 (1H, dd, J=7.6, 2.4 Hz), 6.71 (2H, m), 6.53 (2H, br s), 6.00 (1H, ddd, J=17.4, 10.6, 5.5 Hz), 5.36 (1H, dd, J=17.4, 1.6 Hz), 5.23 (1H, dd, J=10.6, 1.6 Hz), 4.48 (2H, d, J=5.5 Hz), 4.07 (1H, d, J=7.5 Hz), 3.89 (1H, dd, J=16.2, 7.5 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.09, 161.41, 158.26, 156.58, 155.06, 145.35, 133.75, 129.48, 118.78, 117.56, 113.43, 112.03, 91.60, 68.11, 38.50, 32.86; MS (EI) m/z 312 (M+).
2-Amino-5-(3-chloro-4-ethoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2l)
(60) Yield: 30%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.60 (1H, br s), 10.09 (1H, s), 7.15 (1H, s), 7.02 (2H, s), 6.55 (2H, brs), 4.06 (1H, d, J=8.0 Hz), 4.05 (2H, q, J=7.0 Hz), 2.91 (1H, dd, J=16.0, 8.0 Hz), 1.31 (3H, t, J=7.0 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.0, 161.38, 156.52, 155.11, 153.38, 136.81, 127.90, 126.09, 121.07, 113.90, 91.53, 64.28, 38.42, 31.87, 14.57.
2-Amino-5-(3-chlorophenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2m)
(61) Yield: 35%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.61 (1H, br s), 10.11 (1H, s), 7.30 (1H, t, J=8.0 Hz), 7.24 (1H, d, J=8.0 Hz), 7.16 (1H, s), 7.11 (1H, d, J=8.0 Hz), 6.57 (2H, br s), 4.13 (1H, d, J=8.0 Hz), 2.95 (1H, dd, J=16.0, 8.0 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 170.85, 161.42, 156.76, 155.18, 146.35, 133.07, 130.46, 126.49, 126.41, 125.20, 91.61, 38.24, 32.72.
2-Amino-5-(3-bromophenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2n)
(62) Yield: 25%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.61 (1H, br s), 10.12 (1H, s), 7.38 (1H, d, J=8.0, 1.8 Hz), 7.31 (1H, t, J=1.8 Hz), 7.24 (1H, t, J=8.0 Hz), 7.14 (1H, d, J=8.0 Hz), 6.57 (2H, brs), 4.12 (1H, d, J=8.0 Hz), 2.95 (1H, dd, J=16.2.8.0 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 170.81, 161.40, 156.74, 155.18, 146.63, 130.77, 129.38, 129.30, 125.57, 121.78, 91.03, 38.25, 32.71.
2-Amino-5-(3-trifluoromethoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2o)
(63) Yield: 23%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.64 (1H, br s), 10.15 (1H, s), 7.40 (1H, t, J=8.0 Hz), 7.17 (2H, t, J=8.0 Hz), 7.12 (1 s), 6.58 (2H, brs), 4.18 (1H, d, J=7.2 Hz), 2.97 (1H, dd, J=16.2, 7.2 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.26, 161.71, 156.92, 155.40, 148.72, 146.70, 130.66, 120.22 (q, J=254.60 Hz), 119.21, 119.08, 116.41, 91.23, 38.31, 32.81.
2-Amino-5-(3-methoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2p)
(64) Yield: 35%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.60 (1H, br s), 10.07 (1H, s), 7.17 (1H, t, J=7.6 Hz), 6.75 (1H, dd, J=7.6, 2.4 Hz), 6.71 (1H, d, J=2.4 Hz), 6.70 (1H, s), 6.54 (2H, br s), 4.08 (1H, d, J=7.2 Hz), 3.69 (3H, s), 2.92 (1H, dd, J=16.0, 7.2 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.24, 161.45, 159.34, 156.54, 155.11, 145.32, 129.53, 118.56, 112.85, 111.29, 91.65, 54.91, 38.51, 32.89.
2-Amino-5-(3-propoxyphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2q)
(65) Yield: 32%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.58 (1H, br s), 10.05 (1H, s), 7.15 (1H, t, J=8.0 Hz), 6.74-6.67 (3H, m), 6.52 (2H, br s), 4.07 (1H, d, J=8.0 Hz), 3.84 (2H, t, J=6.4 Hz), 2.91 (1H, dd, J=16.4, 8.0 Hz), 1.69 (2H, sext, J=6.4 Hz), 0.94 (3H, t, J=6.4 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.09, 161.47, 158.76, 156.62, 155.05, 145.34, 129.50, 118.54, 112.19, 111.74, 91.68, 68.76, 38.52, 32.89, 22.05, 10.47.
2-Amino-5-biphenyl-3-yl-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2r)
(66) Yield: 37%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.58 (1H, br s), 10.09 (1H, s), 7.53 (2H, dd, J=8.0, 1.2 Hz), 7.42 (5H, m), 7.32 (2H, t, J=8.0 Hz), 7.01 (1H, d, J=8.0 Hz), 6.51 (2H, brs), 4.17 (1H, d, J=7.6 Hz), 2.95 (1H, dd, J=16.0, 7.6 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.38, 161.86, 155.22, 144.66, 140.62, 140.46, 129.37, 129.21, 127.71, 126.94, 126.85, 125.65, 125.20, 91.95, 62.93, 38.71, 33.17.
2-Amino-5-(3-ethylphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2s)
(67) Yield: 37%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.60 (1H, br s), 10.07 (1H, s), 7.15 (1H, t, J=8.0 Hz), 7.01 (1H, d, J=8.0 Hz), 7.00 (1H, s), 6.91 (1H, d, J=8.0 Hz), 6.53 (2H, brs), 4.08 (1H, d, J=7.2 Hz), 2.93 (1, dd, J=16.6, 7.2 Hz), 2.52 (2H, q, J=7.6 Hz), 1.13 (3H, t, J=7.6 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.27, 161.52, 156.60, 155.09, 143.76, 128.43, 126.14, 125.87, 123.66, 91.75, 62.82, 32.95, 28.24, 15.61.
2-Amino-5-(3-propylphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2t)
(68) Yield: 18%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.57 (1H, br s), 10.05 (1H, s), 7.14 (1H, t, J=7.6 Hz), 6.98 (1H, d, J=7.6 Hz), 6.97 (1H, s), 6.91 (1H, d, J=7.6 Hz), 6.52 (2H, br s), 4.07 (1 d, J=8.0 Hz), 2.92 (1H, dd, J=16.2, 8.0 Hz), 1.52 (2H, sext, J=7.2 Hz), 0.86 (3H, t, J=7.2 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.20, 161.48, 156.59, 155.04, 143.66, 142.24, 128.32, 126.63, 126.43, 123.73, 91.75, 38.87, 37.38, 32.90, 24.18, 13.74.
2-Amino-5-(3-butylphenyl)-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione (2u)
(69) Yield: 30%; mp: >300° C.; IR (KBr): cm.sup.−1; .sup.1H NMR (400 MHz, DMSO-d6): δ 10.57 (1H, br s), 10.01 (1H, s), 7.13 (1H, t, J=7.6 Hz), 6.98 (1H, d, J=7.6 Hz), 6.97 (1H, s), 6.90 (1H, d, J=7.6 Hz), 6.52 (2H, brs), 4.07 (1H, d, J=8.0 Hz), 2.92 (1H, dd, J=16.4, 8.0 Hz), 1.48 (2H, quin, J=7.4 Hz), 1.27 (2H, sext, J=7.4 Hz), 0.87 (3H, t, J=7.4 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.16, 161.46, 156.59, 155.04, 143.66, 142.42, 128.33, 126.59, 126.39, 123.67, 91.76, 38.70, 34.93, 33.20, 32.90, 21.82, 13.82. 1) Tu, S. et al. Bioorg. Med. Chem. Lett. 2006, 16, 3578-3581. 2) Muskinja. J. et al. Med. Chem. Res. 2016, 25, 1744-1753. 3) McDonald, B. et al. Org. Lett. 2015, 17, 98-101. 4) US 2015/0210682A 5) JP Patent Publication (Kohyo) 2010-526138 A 6) Wang, B. et al. Eur. J. Org. Chem. 2009, 22, 3688-3692. 7) WO 2008/136756 8) Shi, D. Q. et al. J. Heterocyclic Chem. 2009, 46, 1331-1334.
[Example 2] Synthesis of PA-9 Derivatives
(70) ##STR00013## ##STR00014##
(71) The corresponding amine from the amines 1a to d (1.0 eq) and itaconic acid (1.0 eq) were mixed at room temperature, and the mixture was heated gradually from 60° C. to 150° C. in an Ar atmosphere in accordance with Literature.sup.1) (JP Patent Publication (Kohyo) 2006-510596 A). The mixture was heated at 150° C. for 30 minutes and then cooled to room temperature to obtain carboxylic acids 2a to d, respectively, as pale yellow solids. To a solution of the corresponding carboxylic acid from the carboxylic acids 2a to d (1.0 eq) in DMF were sequentially added at room temperature dicyclohexylcarbodiimide (DCC) (1.2 eq), I-hydroxybenzotriazole (HOBt) (1.2 eq) and histamine (1.2 eq), and the mixture was stirred for 15 hours. A crude product was obtained by distilling off the solvent, and the crude product was purified by silica gel chromatography (CH.sub.2Cl.sub.2:MeOH=5:1) and further washed with EtOAc:MeOH=5:1 (0.5 mL×3) to obtain 3a to d, respectively, as white solids.
1-(4-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxylic acid (2a)
(72) .sup.1H NMR (400 MHz, Pyridine-d5): δ 10.74 (1H, br s), 7.73 (1H, d, J=2.1 Hz), 7.45 (1H, d, J=8.6 Hz), 7.15 (1H, dd, J=2.1.8.6 Hz), 4.65 (1H, dd, J=13.0, 7.6 Hz), 4.44 (1H, t, J=7.6 Hz), 3.40 (1H, quint. J=7.6 Hz), 2.77 (1H, dd, J=17.6, 7.6 Hz), 2.60 (1H, dd, J=17.6, 7.6 Hz).
1-(5-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxylic acid (2b)
(73) .sup.1H NMR (400 MHz, Pyridine-d5): δ 11.53 (1H, br s), 7.38 (1H, d, J=8.4 Hz), 7.14 (1H, dd, J=8.4, 7.2 Hz), 6.93 (1H, d, J=7.2 Hz), 4.67 (1H, dd, J=13.0, 7.5 Hz), 4.52 (1H, t, J=7.5 Hz), 3.39 (1H, quint, J=7.5 Hz), 2.76 (1H, dd, J=17.5, 7.5 Hz), 2.57 (1H, dd, J=17.5, 7.5 Hz).
1-(6-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxylic acid (2c)
(74) .sup.1H NMR (400 MHz, Pyridine-d5): δ 11.63 (1H, br s), 7.71 (1H, d, J=9.0 Hz), 7.48 (1H, d, J=1.7 Hz), 6.88 (1H, dd, J=9.0, 1.7 Hz), 4.65 (1H, dd, J=13.0, 7.7 Hz), 4.44 (1H, t, J=7.7 Hz), 3.40 (1H, quint, J=7.7 Hz), 2.68 (1H, dd, J=17.1, 7.7 Hz), 2.60 (1H, dd, J=17.1, 7.7 Hz).
1-(7-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxylic acid (2d)
(75) .sup.1H NMR (400 MHz, Pyridine-d5): δ 11.66 (1H, br s), 7.67 (1H, d, J=8.7 Hz), 7.30 (1H, d, J=7.3 Hz), 6.86 (1H, dd, J=8.7, 7.3 Hz), 4.71 (1H, dd, J=13.4, 7.4 Hz), 4.48 (1H, t, J=7.4 Hz), 3.42 (1H, quint, J=7.4 Hz), 2.78 (1H, dd, J=17.6, 7.4 Hz), 2.61 (1H, dd, J=17.6, 7.4 Hz).
N-[2-(1H-imidazol-4-yl)ethyl]-1-(4-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxamide (3a)
(76) mp: 190-191° C.; IR (KBr): 3566, 3437, 3306, 1695, 1636, 1558, 1508 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.00 (H, br s), 7.96 (1H, s), 7.61 (1H, d, J=7.4 Hz), 7.14 (1H, t, J=7.4 Hz), 7.15 (1H, s), 6.98 (1H, d, J=7.4 Hz), 4.72 (1H, t, J=9.1 Hz), 3.96-3.85 (3H, m), 3.26 (1H, dd, J=15.6, 9.1 Hz), 3.11 (2H, t, J=6.8 Hz), 2.78 (1H, dd, J=15.6, 9.1 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 169.56, 168.62, 147.59, 134.59, 131.61, 126.70, 123.80, 119.28, 116.97, 115.67, 107.11, 48.23, 36.47, 32.61, 26.57.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(5-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxamide (3b)
(77) Yield: 24% over two steps; mp: 208-209° C.; IR (KBr): 3735, 3649, 3097, 1684, 1653, 1558, 1508 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.04 (1H, br s), 8.05 (1H, s), 7.69 (1H, d, J=9.6 Hz), 7.68 (1H, s), 7.27 (1H, d, J=9.6 Hz), 7.71 (1H, s), 5.09 (1H, dd, J=13.6, 8.4 Hz), 4.73 (1H, t, J=8.4 Hz), 3.94-3.86 (3H, m), 3.28 (1H, dd, J=14.8, 8.4 Hz), 3.11 (2H, t, J=6.6 Hz), 2.84 (1H, dd, J=14.8, 8.4 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 169.63, 168.21, 145.55, 134.50, 133.79, 131.92, 127.15, 123.19, 118.50, 118.39, 116.85, 108.13, 48.33, 38.747, 36.33, 32.92, 26.53.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(6-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxamide (3c)
(78) Yield: 17% over two steps: mp: 196-198° C.; IR (KBr): 3290, 3213, 3101, 1683, 1636, 1558, 1508 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.12 (1H, br s), 8.30 (1H, s), 7.83 (1H, s), 7.66 (1H, d, J=9.2 Hz), 7.25 (1H, s), 6.96 (1H, d, J=9.2 Hz), 5.03 (1H, dd, J=13.0, 8.3 Hz), 4.71 (1H, t, J=8.3 Hz), 3.91-3.84 (3H, m), 3.27 (1H, dd, J=15.2, 8.3 Hz), 3.12 (2H, t, J=6.4 Hz), 2.87 (1H, dd, J=15.2, 8.3 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 169.79, 168.28, 147.25, 134.03, 132.74, 132.42, 131.35, 121.77, 119.93, 116.53, 115.03, 106.65, 48.23, 38.21, 36.25, 32.92, 25.47.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(7-chloro-1H-indazol-3-yl)-5-oxo-3-pyrrolidinecarboxamide (3d)
(79) Yield: 36% over two steps; mp: 238-239° C.; IR (KBr): 3319, 3231, 3213, 1663, 1636, 1558, 1508 cm.sup.1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.02 (1H, br s), 8.49 (1H, s), 7.76 (1H, s), 7.52 (1H, d, J=7.5 Hz), 7.40 (1H, 1d, J=7.5 Hz), 6.98 (1H, s), 6.88 (1H, 1t, J=7.5 Hz), 5.13 (1H, dd, J=14.6, 8.5 Hz), 4.81 (1H, t, J=8.5 Hz), 3.95-3.86 (3H, m), 3.26 (1H, dd, J=16.2, 8.5 Hz), 3.11 (2H, t, J=6.8 Hz), 2.83 (1H, dd, J=16.2, 8.5 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 169.56, 168.32, 144.32, 134.51, 133.83, 133.30, 125.80, 120.48, 119.42, 119.04, 116.84, 109.42, 48.36, 38.77, 36.32, 32.95, 26.57.
(80) To an aqueous solution of the corresponding amine from the amines 1e to j (1.0 eq) (3 mL) was added at room temperature itaconic acid (1.2 eq), and the mixture was heated and refluxed with stirring for 20 hours in an Ar atmosphere in accordance with Literature.sup.2) (JP Patent Publication (Kohyo) No. 2012-529476 A). The mixture was cooled to room temperature, and a depositing solid was then filtered to obtain carboxylic acids 2e to j, respectively. To a solution of the corresponding carboxylic acid from the carboxylic acids 2e to j (1.0 eq) in a mixture of CH.sub.2Cl.sub.2 and DMF were sequentially added at room temperature 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (1.2 eq), 4-dimethylaminopyridine (DMAP) (0.1 eq) and histamine (1.2 eq), and the mixture was stirred for 15 hours. A crude product was obtained by distilling off the solvent, and purified by silica gel chromatography (CH.sub.2Cl.sub.2:MeOH=10:1) to obtain 3e to j, respectively, as white solids.
N-[2-(1H-imidazol-4-yl)ethyl]-1-phenyl-5-oxo-3-pyrrolidinecarboxamide (3e)
(81) Yield: 63%; mp: 149-151° C.; IR (KBr): 3675, 3306, 1678, 1643, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.11 (1H, t, J=5.8 Hz), 7.90 (1H, s), 7.72 (2H, d, J=8.4 Hz), 7.28 (2H, t, J=8.4 Hz), 7.09 (1H, s), 7.06 (1H, t, J=8.4 Hz), 4.13 (1H, dd. J=9.6, 8.3 Hz), 3.93 (1H, t, J=8.3 Hz), 3.83 (2H, q, J=7.5 Hz), 3.47 (1H, quint, J=8.3 Hz), 3.14 (1H, dd, J=16.7, 8.3 Hz), 3.08 (2H, t, J=7.5 Hz), 2.84 (1H, dd, J=16.7, 8.3 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.16, 171.96, 139.22, 134.58, 133.95, 128.70, 124.00, 119.36, 116.83, 50.73, 38.66, 35.66, 35.43, 26.38.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(4-methylphenyl)-5-oxo-3-pyrrolidinecarboxamide (3f)
(82) Yield: 93%; mp: 176-178° C.; IR (KBr): 3306, 3088, 1675, 1639, 1556 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.10 (H, t, J=5.8 Hz), 7.91 (1H, s), 7.64 (2H, d, J=7.2 Hz), 7.08 (2H, t, J=7.2 Hz), 7.07 (1H, s), 4.14 (1H, dd, J=9.6, 8.0 Hz), 3.92 (1H, t, J=8.0 Hz), 3.83 (2H, q, J=7.2 Hz), 3.46 (1H, quint, J=8.0 Hz), 3.14 (1H, dd, J=17.6, 8.0 Hz), 3.08 (2H, t, J=7.2 Hz), 2.84 (1H, dd, J=17.6, 8.0 Hz), 2.13 (3H, s); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.17, 172.10, 137.00, 134.86, 134.44, 133.26, 129.30, 119.58, 117.04, 51.00, 39.17, 36.02, 35.84, 27.01, 20.63.
1-(4-chlorophenyl)-N-[2-(1H-imidazol-4yl)ethyl]-5-oxo-3-pyrrolidinecarboxamide (3g)
(83) Yield: 93%; mp: 196-198° C.; IR (KBr): 3119, 3017, 1695, 1647, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.16 (H, t, J=5.2 Hz), 7.95 (1H, s), 7.71 (2H, d, J=8.4 Hz), 7.30 (2H, d, J=8.4 Hz), 7.11 (1H, s), 4.10 (1H, dd, J=9.4.8.3 Hz), 3.92 (1H, t, J=8.3 Hz), 3.83 (2H, q, J=6.7 Hz), 3.50 (1H, quint, J=8.3 Hz), 3.11 (1H, dd, J=17.5, 8.3 Hz), 3.09 (2H, t, J=5.7 Hz), 2.85 (1H, dd. J=17.5, 8.3 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.20, 171.68, 137.90, 134.43, 133.95, 128.36, 127.49, 120.60, 116.62, 50.47, 38.74, 35.62, 35.30, 26.52.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(4-fluorophenyl)-5-oxo-3-pyrrolidinecarboxamide (3h)
(84) Yield: 94%; mp: 232-234° C.; IR (KBr): 3140, 3126, 1688, 1645, 1570 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.13 (1H, t, J=4.8 Hz), 7.72-7.68 (2H, m), 7.92 (1H, s), 7.11 (1H, s), 7.09-7.04 (2H, m), 4.12 (1H, dd, J=12.2, 8.7 Hz), 3.92 (1H, t, J=8.7 Hz), 3.84 (2H, t, J=7.0 Hz), 3.49 (1H, quint, J=8.7 Hz), 3.14 (1H, dd, J=17.2, 8.7 Hz), 3.09 (2H, t, J=7.0 Hz), 2.85 (1H, dd, J=17.2, 8.7 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.05, 171.90, 158.44 (d, J=240.3 Hz), 135.64, 134.62, 134.14, 121.35 (d, J=7.6 Hz), 116.81, 115.25 (d, J=22.0 Hz), 50.92, 38.92, 35.68, 35.58, 26.72.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(4-methoxyphenyl)-5-oxo-3pyrrolidinecarboxamide (3i)
(85) Yield: 95%; mp: 151-153° C.; IR (KBr): 3239, 3075, 1684, 1635, 1568 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.08 (1H, t, J=5.2 Hz), 7.91 (1H, s), 7.68 (2H, d, J=8.6 Hz), 7.10 (1H, s), 6.92 (2H, d, J=8.6 Hz), 4.16 (1H, dd, J=9.4, 8.4 Hz), 3.93 (1H, t, J=8.4 Hz), 3.84 (2H, q, J=7.6 Hz), 3.62 (3H, s), 3.46 (1H, quint, J=8.4 Hz), 3.15 (1H, dd, J=17.1, 8.4 Hz), 3.09 (2H, t, J=7.6 Hz), 2.84 (1H, dd, J=17.1, 8.4 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 171.97, 171.57, 155.80, 134.65, 134.26, 132.41, 121.20, 116.80, 113.82, 55.20, 51.03, 38.95, 35.68, 35.62, 26.81.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(4-cyanophenyl)-5-oxo-3-pyrrolidinecarboxamide (3j)
(86) Yield: 69%; mp: 211-212° C.; IR (KBr): 3151, 3019, 2231, 1703, 1646, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.17 (1H, t, J=5.2 Hz), 7.92 (1H, s), 7.83 (2H, d, J=8.8 Hz), 7.60 (2H, d, J=8.8 Hz), 7.11 (1H, s), 4.12 (H, dd, J=9.6, 8.4 Hz), 3.96 (1H, t, J=8.4 Hz), 3.84 (2H, t, J=7.0 Hz), 3.51 (1H, quint, J=8.4 Hz), 3.16 (1H, dd, J=17.2, 8.4 Hz), 3.10 (2H, t, J=7.0 Hz), 2.88 (H, dd, J=17.2, 8.4 Hz).sup.13C NMR (100 MHz, DMSO-d6): δ 173.28, 171.75, 143.03, 134.67, 133.06, 119.03, 118.93, 105.53, 51.51, 38.98, 36.03, 35.39, 26.85.
(87) The corresponding amine from the amines k to m (1.0 eq) and itaconic acid (1.0 eq) were mixed at room temperature, and the mixture was heated gradually from 60° C. to 150° C. in an Ar atmosphere in accordance with Literature.sup.1 (JP Patent Publication (Kohyo) 2006-510596 A). The mixture was heated at 150° C. for 30 minutes and then cooled to room temperature to obtain carboxylic acids 2k to m, respectively. To a solution of the corresponding carboxylic acid from the carboxylic acids 2k to m (1 eq) in a mixture of CH.sub.2Cl.sub.2 and DMF were sequentially added at room temperature EDC (1.2 eq), DMAP (0.1 eq) and histamine (1.2 eq), and the mixture was stirred for 15 hours. A crude product was obtained by distilling off the solvent, and purified by silica gel chromatography (CH.sub.2Cl.sub.2:MeOH=10:1) to obtain 3k to m as white, yellow and red foamy solids, respectively.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(2-hydroxyphenyl)-5-oxo-3-pyrrolidinecarboxamide (3k)
(88) Yield: 40%; IR (KBr): 3651, 3265, 3213, 1684, 1670, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 9.08 (1H, br s), 7.91 (1H, s), 7.42 (1H, d, J=8.8 Hz), 7.21-7.15 (2H, m), 7.10 (1H, s), 6.92-6.88 (1H, m), 4.30 (1H, dd, J=9.2, 7.5 Hz), 4.10 (1H, t, J=7.5 Hz), 3.85 (2H, q, J=6.4 Hz), 3.47 (1H, quint, J=7.5 Hz), 3.13 (1H, dd, J=16.4, 7.5 Hz), 3.06 (2H, t, J=6.4 Hz), 2.83 (1H, dd, J=16.4, 7.5 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.52, 172.22, 152.77, 134.68, 128.30, 128.24, 125.48, 119.12, 118.74, 116.87, 116.74, 51.68, 38.98, 37.09, 34.39, 26.85.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(3-hydroxyphenyl)-5-oxo-3-pyrrolidinecarboxamide (31)
(89) Yield: 58%; IR (KBr): 3790, 3439, 3337, 1684, 1653, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 8.97 (1H, br s), 8.09 (1H, s), 7.93 (1H, s), 7.28 (1H, t, J=8.2 Hz), 7.20 (1H, d, J=8.2 Hz), 7.13 (1H, s), 6.98 (1H, d, J=8.2 Hz), 4.29 (1H, dd, J=9.0, 8.3 Hz), 3.98 (1H, t, J=8.3 Hz), 3.89 (2H, q, J=6.9 Hz), 3.36 (1H, quint, J=8.3 Hz), 3.21 (1H, dd, J=17.1, 8.3 Hz), 3.09 (2H, t, J=6.9 Hz), 2.82 (1H, dd, J=17.1, 8.3 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.07, 171.93, 157.55, 140.28, 134.68, 129.38, 111.17, 109.78, 106.63, 50.84, 39.00, 35.99, 35.54, 26.89.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(4-hydroxyphenyl)-5-oxo-3-pyrrolidinecarboxamide (3m)
(90) Yield: 54%; IR (KBr): 3585, 3251, 3190, 1684, 1653, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 11.49 (1H, br s), 8.97 (1H, br s), 7.93 (1 s), 7.76 (2H, dd, J=8.6, 2.4 Hz), 7.15 (2H, dd, J=8.6, 2.4 Hz), 7.14 (1H, s), 4.29 (1H, td, J=8.4, 2.1 Hz), 3.95 (1H, td, J=8.4, 2.1 Hz), 3.90 (2H, q, J=6.3 Hz), 3.39 (1H, quint, J=8.4 Hz), 3.22 (1H, ddd, J=16.7, 8.4, 2.1 Hz), 3.10 (2H, t, J=6.3 Hz), 2.84 (1H, ddd, J=16.7, 8.4, 2.1 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.52, 171.86, 154.61, 135.20, 131.48, 122.05, 115.61, 51.67, 39.49, 36.23, 36.09, 27.40.
(91) An amine in (1.0 eq) and itaconic acid (1.0 eq) were mixed at room temperature, and the mixture was heated gradually from 60° C. to 150° C. in an Ar atmosphere in accordance with Literature.sup.1) (JP Patent Publication (Kohyo) 2006-510596 A). The mixture was heated at 150° C. for 30 minutes and then cooled to room temperature to obtain a carboxylic acid 2n. To a solution of the carboxylic acid 2n (1.0 eq) in a mixture of CH.sub.2Cl.sub.2 and DMF were sequentially added at room temperature DCC (1.2 eq), HOBt (1.2 eq) and histamine (1.2 eq), and the mixture was stirred for 15 hours. A crude product was obtained by distilling off, and purified by silica gel chromatography (CH.sub.2Cl.sub.2:MeOH=10:1) to obtain 3n as a white solid.
N-[2-(1H-imidazol-4-yl)ethyl]-1-(1H-pyrazol-3-yl)-5-oxo-3-pyrrolidinecarboxamide (3n)
(92) Yield: 30%; mp: 213-211° C.; IR (KBr): 3676, 3320, 3203, 1689, 1652, 1635, 1557 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 12.24 (1H, br s), 9.00 (1H, br s), 8.03 (1H, s), 7.88 (1H, s), 7.56 (1H, s), 7.10 (1H, s), 4.78 (1H, dd, J=12.6, 8.1 Hz), 4.26 (1H, t, J=8.1 Hz), 3.82 (2H, q, J=6.7 Hz), 3.69 (1H, quint, J=8.1 Hz), 3.22 (1H, dd. J=15.3, 8.1 Hz), 3.06 (2H, t, J=6.7 Hz), 2.72 (1H, dd, J=15.3, 8.1 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 169.67, 168.26, 162.33, 138.77, 138.73, 134.64, 134.53, 89.01, 47.04, 38.87, 36.72, 33.00, 26.97.
(93) The corresponding amine from the amines 1o to r (1.0 eq) and itaconic acid (1.0 eq) were mixed at room temperature, and the mixture was heated gradually from 60° C. to 150° C. in an Ar atmosphere in accordance with Literature.sup.1 (JP Patent Publication (Kohyo) 2006-510596 A). The mixture was heated at 150° C. for 30 minutes, then cooled to room temperature and purified by silica gel chromatography (CH.sub.2Cl.sub.2:MeOH=30:1) to obtain carboxylic acids 2o to r, respectively. To a solution of the corresponding carboxylic acid from the carboxylic acids 2o to r (1.0 eq) in a mixture of CH.sub.2Cl.sub.2 and DMF were sequentially added at room temperature DCC (1.2 eq), HOBt (1.2 eq) and histamine (1.2 eq), and the mixture was stirred for 15 hours. A crude product was obtained by distilling off the solvent, and purified by silica gel chromatography (CH.sub.2Cl.sub.2:MeOH=10:1) to obtain 3o to r, respectively, as a yellow solid or a white foamy solid.
N-[2-(1H-imidazol-4yl)ethyl]-5-oxo-1-(phenylmethyl)-3-pyrrolidinecarboxamide (3o)
(94) Yield: 29%; IR (KBr): 3271, 3155, 1670, 1652, 1558 cm.sup.−1; H NMR (400 MHz, Pyridine-d5): δ 8.85 (1H, br), 7.92 (1H, s), 7.33-7.25 (5H, m), 7.08 (1H, s), 4.56 (H, d, J=14.6 Hz), 4.48 (1H, d, J=14.6 Hz), 3.85 (2H, q, J=6.5 Hz), 3.67 (1H, t, J=8.0 Hz), 3.39 (1H, t, J=8.0 Hz), 3.25 (1H, quint, J=8.0 Hz), 3.10 (11H, dd, J=17.0, 8.0 Hz), 3.05 (2H, t, J=6.5 Hz), 2.72 (1H, dd, J=17.0, 8.0 Hz).
N-[2-(1H-imidazol-4-yl)ethyl]-1-[(2-hydroxyphenyl)methyl]-5-oxo-3-pyrrolidinecarboxamide (3p)
(95) Yield: 30%; IR (KBr): 3748, 3738, 3651, 1684, 1653, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 11.36 (1H, br s) 8.81 (1H, t, J=5.8 Hz), 7.84 (1H, d, J=1.2 Hz), 7.34 (1H, dd, J=7.5, 1.3 Hz), 7.13 (1H, td, J=7.5, 1.3 Hz), 7.08 (1H, dd, J=7.5, 1.3 Hz), 7.03 (1H, s), 6.81 (1H, td, J=1.3, 7.5 Hz), 4.74 (1H, d, J=15.2 Hz), 4.65 (1H, d, J=15.2 Hz), 3.82 (1H, dd, J=9.6, 8.2 Hz), 3.77 (2H, q, J=6.6 Hz), 3.57 (1H, t, J=8.2 Hz), 3.22 (1H, quint, J=8.2 Hz), 3.03 (1H, dd, J=16.5, 8.2 Hz), 2.99 (2H, t, J=6.6 Hz), 2.63 (1H, dd, J=16.5, 8.2 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.57, 172.18, 155.26, 134, 67, 128.78, 128.38, 122.58, 119.03, 115.21, 49.63, 40.57, 38.94, 35.93, 33.91, 26.87.
N-[2-(1H-imidazol-4-yl)ethyl]-1-[(3-hydroxyphenyl)methyl]-5-oxo-3-pyrrolidinecarboxamide (3q)
(96) Yield: 40%; IR (KBr): 3734, 3647, 3623, 1684, 1653, 1558 cm.sup.−1; .sup.1H NMR (40 MHz, Pyridine-d5): δ 8.83 (1H, br s), 7.93 (1H, s), 7.24 (2H, d, J=7.9 Hz), 7.22 (1H, s), 7.09 (1H, s), 7.08 (1H, d, J=7.9 Hz), 6.88 (1H, d, J=7.9 Hz), 4.57 (1H, d, J=14.6 Hz), 4.48 (1H, d, J=14.6 Hz), 3.84 (2H, q, J=6.1 Hz), 3.72 (1H, t, J=8.1 Hz), 3.45 (11H, t, J=8.1 Hz), 3.23 (1H, quint, J=8.1 Hz), 3.09 (1H, dd, J=16.0, 8.1 Hz), 3.05 (2H, t, J=6.1 Hz), 2.67 (1H, dd, J=16.0, 8.1 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.31, 172.05, 157.63, 138.14, 134.66, 134.18, 129.55, 118.17, 116.90, 114.41, 114.30, 49.14, 45.31, 38.88, 35.89, 26.78.
N-[2-(1H-imidazol-4-yl)ethyl]-1-[(4-hydroxyphenyl)methyl]-5-oxo-3-pyrrolidinecarboxamide (3r)
(97) Yield: 29%; IR (KBr): 3651, 3271, 3213, 1663, 1653, 1558 cm.sup.−1; .sup.1H NMR (400 MHz, Pyridine-d5): δ 8.85 (1H, br s), 7.91 (1H, s), 7.28 (2H, d, J=7.6 Hz), 7.10 (2H, d, J=7.6 Hz), 4.55 (1H, d, J=14.6 Hz), 4.44 (1H, d, J=14.6 Hz), 3.91-3.71 (2H, m), 3.70 (1H, dd, J=8.8, 7.9 Hz), 3.45 (1H, t, J=7.9 Hz), 3.26 (1H, quint, J=7.9 Hz), 3.11 (1H, dd. J=15.0, 7.9 Hz), 3.06 (2H, t, J=7.4 Hz), 2.71 (1H, dd, J=15.0, 7.9 Hz); .sup.13C NMR (100 MHz, DMSO-d6): δ 172.15, 156.66, 134.68, 129.07, 126.80, 115.30, 48.93, 44.83, 38.94, 35.83, 34.03, 26.89. 1) JP Patent Publication (Kohyo) 2006-510596 A 2) JP Patent Publication (Kohyo) 2012-529476 A 3) Saczewski, F. et al. Bioorg. Med. Chem. 2011, 19, 321-329 4) Mestichelli, P. et al. Org. Lett. 2013, 15, 5448-5451 5) Commercially available, Aurora Building Blocks, A17.818.885 6) Commercially available, Aurora Building Blocks, A21.884.126
[Example 3] Drug Efficacy Evaluation Using PACAP Receptor-Expressing. Cultured Cells
(98) The effect of each compound on the phosphorylation of CREB (cAMP-responsive element-binding protein) produced by a PACAP stimulus was examined by Western blot analysis using an anti-phosphorylated CREB (pCREB) antibody with a mouse PAC receptor-expressing CHO cell (PAC1/CHO cell) and a mouse VPAC1 receptor-expressing CHO cell (VPAC1/CHO cell).
(99) Specifically, treatment with a compound (PA-8, PA-9, compounds 2j, 20 and 3d) at 10 μM to 10 nM or a solvent therefor (VEH: 0.1% DMSO-containing phosphate buffer solution) was performed for 30 minutes, 1 nM PACAP was then added, and protein was recovered within 30 minutes after a PACAP stimulus.
(100)
(101)
(102) As PA-8 and PA-9 used in the experiments, commercial compounds purchased from NAMIKI SHOJI CO., LTD. were used.
[Example 4] Drug Efficacy Evaluation 1 Using Mouse Pain Model (Spontaneous Pain-Like Behavior Induced by PACAP Intrathecal Administration)
(103) When PACAP (100 pmol/5 L) is intrathecally administered to a mouse in a single dose (single i.t. injection), spontaneous pain-like behavior in which the mouse licks or bites the rear half of the body occurs about 5 minutes after the administration (and continues for several hours) (Ohnou et al. J. Pharmacol. Sci. 130, 194-203, 2016).
(104) When simultaneous i.t. administration of PACAP (100 pmol) and PA-8, the compound 2j or the compound 20 (10 to 100 pmol/5 μL) was performed, all except the compound 20 (10 pmol) suppressed the PACAP response significantly, and the effect of the compound 2j (10 pmol) was significantly stronger than that of PA-8 (10 pmol), and was an effect equivalent or superior to that of PA-8 (100 pmol). Meanwhile, although the compound 20 did not exhibit a significant suppressing effect at 10 pmol, the compound 2o exhibited a suppressing effect equivalent to PA-8 and the compound 2j at 100 pmol (n=7 to 8,
(105) Male ddY mice (6 to 12 weeks old) were used, and the behaviors were taken on video. The number of times of spontaneous pain-like behaviors for 30 minutes after the administration was counted.
[Example 5] Drug Efficacy Evaluation 2 Using Mouse Pain Model (Mechanical Allodynia Induced by PACAP Intrathecal Administration)
(106) When single i.t. administration of PACAP (100 pmol/5 L) to mouse was performed, mechanical stimulus sensitive phenomenon (mechanical allodynia) occurred over a long period of time (for at least three months after the administration) (Non Patent Literature 1). The occurrence of this long-term mechanical sensitive phenomenon induced by PACAP was strongly suppressed by simultaneous i.t. administration of PA-8, the compound 2j or the compound 2 (10 or 100 pmol,
(107) Male ddY mice (6 to 12 weeks old) were used, and the threshold to a mechanical stimulus was evaluated by the vonFrey test. Specifically, the 50% withdrawal reflex threshold (Threshold) was calculated in accordance with the method of Chaplan et al. (Chaplan et al., J. Neurosci. Meth. 53, 55-63, 1994). Each compound was dissolved in 99.7% DMSO, and then the resulting solution was diluted with an artificial cerebrospinal fluid for preparation (final concentration of DMSO was 0.2%).
[Example 6] Drug Efficacy Evaluation 3-1 Using Mouse Pain Model (Neuropathic Pain Model Associated with Cancer Chemotherapy: Cold Allodynia Induced by Oxaliplatin)
(108) Oxaliplatin was dissolved in 5% glucose-containing saline and intraperitoneally administered at a dose of 2 mg/kg. A drug was administered on the fourth day after oxaliplatin administration. Male ddY mice (6 to 12 weeks old) were used. The axis of ordinates is the duration of the behavior of licking and paw waving after the application of an acetone drop (10 L) to the footpad of a hind paw. Although a solvent (VEH: 100% DMSO aqueous solution) had no effect, PA-8, the compound 2j and the compound 2o (10 mg/kg, single oral administration) each suppressed cold allodynia by oxaliplatin significantly over 4 to 5 hours, and the compound 20 was effective from an earlier period of time (the first hour after administration) (
[Example 7] Drug Efficacy Evaluation 3-2 Using Mouse Pain Model (Neuropathic Pain Model Associated with Cancer Chemotherapy: Cold Allodynia Induced by Oxaliplatin)
(109) Oxaliplatin was dissolved in 5% glucose-containing saline and intraperitoneally administered at a dose of 2 mg/kg. Drug administration (oral administration) was performed 30 minutes before oxaliplatin administration (
[Example 8] Drug Efficacy Evaluation 4 Using Mouse Pain Model (Peripheral Neuropathic Pain Model: Mechanical Allodynia Induced by Spinal Nerve Injury)
(110) Spinal nerve ligation (SNL) models in which the fourth lumbar cord spinal nerves of male ddY (6 to 12 weeks old) were ligated with silk thread were used. A solvent (VEH: 10% DMSO-containing saline). PA-8, the compound 2j or the compound 20 was intraperitoneally administered (30 mg/kg) 5 to 10 minutes before the ligation, and once a day for 7 days thereafter. The method of causing a mechanical stimulus is the same as that of Example 5, and data from the first day after the ligation (D1) are data 1 hour after the administration of VEH or the drugs. The compound 2j did not suppress the onset of mechanical allodynia as in the VEH group. Meanwhile, although PA-8 suppressed the onset of mechanical allodynia significantly, the compound 20 suppressed the onset of mechanical allodynia still more strongly, and maintained the mechanical threshold at a level equivalent to an uninjured side. As for PA-8 and the compound 2o, even though the administration was discontinued on the seventh day, the compound maintained the mechanical threshold highly significantly for at least 7 days thereafter as compared with the VEH group (
[Example 9] Drug Efficacy Evaluation 5 Using Mouse Pain Model (Peripheral Neuropathic Pain Model: Mechanical Allodynia Induced by Spinal Nerve Injury)
(111) Spinal nerve ligation (SNL) models in which the fourth lumbar cord spinal nerves of male ddY (6 to 12 weeks old) were ligated with silk thread were used. The i.t. administration of a solvent (VEH: 10% DMSO-containing saline), PA-8, the compound 2j or the compound 2o (
(112) Although PA-8, the compound 2o and the compound 2j (100 pmol each) suppressed the onset of mechanical allodynia significantly, the maximum effect of the compound 2j (3 hours after the administration) was significantly inferior as compared with the compound 2o. PA-9 and the compound 3d (100 pmol each) also exhibited an anti-mechanical allodynia effect equivalent to PA-8 and the compound 2j, and also maintained the mechanical threshold highly significantly 24 hours after the administration.
[Example 10] Drug Efficacy Evaluation 6 Using Mouse Pain Model (Pain-Like Behavior Induced by Formalin)
(113) When formalin is subcutaneously injected into a hind paw of a mouse, the animal exhibits pain-like behavior such as licking or brandishing the injected hind paw. This behavior exhibits two phases. The first phase is direct action of formalin on sensory nerves (to around 10 minutes after formalin administration). In the second phase (from around 10 minutes to 60 minutes after formalin administration), hypersensitization formed in spinal dorsal horn cells during the first phase (a type of plastic phenomenon in the nervous system also called central sensitization) is a main cause, and inflammatory reaction at the site of formalin administration contributes importantly.
(114) The i.t. administration of PA-8, the compound 2j or the compound 2o (0.1 to 10 nmol) did not affect the first phase reaction (
(115) All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.
REFERENCE SIGNS LIST
(116) VEH (Vehicle) Solvent ipsi ipsilateral contra contralateral